A Randomized, Placebo-Controlled, Double-Blind, Sponsor-Unblinded, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Cycling or Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2010
At a glance
- Drugs PRA 027 (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- 07 Sep 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.